Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05592015 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Jul 31, 2026 → Jul 31, 2027
See other at-risk trials from Jonathan Brammer

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Jul 31, 2026 to Jul 31, 2027
    • Eligibility criteria shortened, about 53 words
    • Secondary endpoints: details revised at 4 of 6 entries
    • Study description revised
  2. Primary and study completion dates: Dec 31, 2025 to Jul 31, 2026
    • Enrollment target: 28 to 30
    v7
  3. Eligibility criteria expanded, about 191 words
    • Study description expanded, about 19 words
    v6
  4. Study sites: 2 to 3v5
  5. Lead sponsor: John Reneau to Jonathan Brammerv4 Show 4 more changesShow less
    • Primary completion date: Dec 31, 2024 to Dec 31, 2025
    • Eligibility criteria expanded, about 70 words
    • Study description shortened, about 23 words
    • Site contacts updated at 1 of 2 sites
Show 2 earlier versionsHide 2 earlier versions
  1. Study sites: 1 to 2v3
  2. Lead sponsor: Ohio State University Comprehensive Cancer Center to John Reneau
    • Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Dec 1, 2022 to May 3, 2023
    • Site details revised
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Jonathan Brammer
3 trials monitored
See 1 trial at risk
Leukemia
2,948 trials monitored
See 180 trials at risk
This phase II trial tests whether ruxolitinib works to shrink tumors in patients with T-cell large granular lymphocyte leukemia. Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Trial Details
NCT Number NCT05592015
Lead Sponsor Jonathan Brammer
Conditions
(from sponsor)		 T-Cell Large Granular Lymphocyte Leukemia
Related terms Leukemia, Large Granular Lymphocytic
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov